Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

74.34 +0.20 (+0.27%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,196,725
Open 74.38
Bid (Size) 74.34 (11)
Ask (Size) 74.54 (1)
Prev. Close 74.14
Today's Range 73.75 - 75.01
52wk Range 62.07 - 87.86
Shares Outstanding 1,253,809,440
Dividend Yield 4.04%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
FDA Approves Gilead's Seladelpar For Inflammatory Liver Disease, Acquired Via $4B CymaBay Deal
FDA grants accelerated approval to Gilead's Livdelzi (seladelpar) for primary biliary cholangitis, offering new treatment options for patients with inadequate response to standard therapy. Continued... 
Via Benzinga
Exposures Product Safety
Expert Outlook: Gilead Sciences Through The Eyes Of 8 Analysts
Via Benzinga

Performance

YTD
-10.69%
-10.69%
1 Month
+3.77%
+3.77%
3 Month
+9.55%
+9.55%
6 Month
+1.32%
+1.32%
1 Year
-4.69%
-4.69%

More News

Read More
Gilead’s Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA
From Gilead Sciences, Inc.
Via Business Wire
7 Defensive Stocks to Buy as Investors Seek Shelter
Via InvestorPlace
3 Stocks Retirees Should Absolutely Love
Via The Motley Fool
Gilead Eyes A Breakout After Second-Quarter Sales, Earnings Beat
Via Investor's Business Daily
$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Gilead Sciences's Options Frenzy: What You Need to Know
Via Benzinga
Analysts Cite Improved Investor Sentiment For Gilead, But Warn of Limited Growth at Current Stock Levels
Via Benzinga
Wall Street Momentum Stalls After Thursday's Rally, Palantir Jumps To 3-Year Highs, Bonds Rally: What's Driving Markets Friday?
Via Benzinga
Gilead Sciences (GILD) Q2 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
$100 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today
Via Benzinga
GILD Stock Earnings: Gilead Sciences Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Gilead Sciences Announces Second Quarter 2024 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
Wall Street Set For Uneventful Start Ahead Of Jobless Claim Data, VIX Rises: Strategist Says Market May Remain Vulnerable Until...
Via Benzinga
Topics Economy Stocks
Exposures Economy US Equities
Wall Street Rallies As Economic Concerns Recede, Tech Flexes Its Muscles, Semiconductors Soar: What's Driving Markets Thursday?
Via Benzinga
Four Stocks To Watch This Week - Monday, August 5
Via Talk Markets
2 Unstoppable Dividend Stocks to Buy if There's a Stock Market Sell-Off
Via The Motley Fool
Q3’s Rising Stars: 3 Nasdaq Stocks for Your Must-Watch List
Via InvestorPlace
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Via Benzinga
The Top 3 Biotech Stocks to Buy Now Summer 2024
Via InvestorPlace
Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?
Via InvestorPlace
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Nasdaq 100 Falls To 7-Week Lows, Marks Worst 2-Day Drop In Nearly 2 Years As Tech Rout Rages On
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.